AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01613612 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Enriched BMCs implantation combined with core decompression
Description: Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
Study NCT02211339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer facilitator training
Description: Peer facilitation of a project-based activity without staff present
Study NCT02211339 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Staff-led social activity
Study NCT00430040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol Controlled Release (CR)
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study.~Initial dose: Carvedilol CR (20 mg QD, dose level 1) Titration: If tolerated, increase the dosage to 20 mg QD, 40 mg QD, and 80mg QD orally over successive intervals of at least 2 weeks to achieve target blood pressure sSBP \<130 and sDBP \< 80
Study NCT00430040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lisinopril
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
Study NCT00430040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisinopril
Description: lisinopril starting dose in all patients 10 mg QD for 1 week then increase to 20 mg QD throughout the study
Study NCT00825071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 8 mg, Intravenous
Study NCT00825071 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: 4 mg, intravenously
Study NCT00825071 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2 ml, intravenously
Study NCT02139189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P-ECM Implant
Description: P-ECM Implant into damaged ischemic and/or infarcted myocardium
Study NCT01358110 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early palliative care consultation
Description: Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
Study NCT01358110 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Care as usual
Description: Standard care as usual which may or may not include palliative care consultation
Study NCT04807491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kabat Technique's
Description: As with all cranial nerves, some specific techniques can also be applied on the facial nerve to enhance responses and improve recovery; the most important are: The rhythmic start: shows and guides the subject into the movements and the scheme; agonist investigation utilizes sequential concentric and eccentric contractions; The inversion of the antagonist: reinforces responses through the induction phenomenon; Repeated contractions: calls for a response with repeated stretching that briefly enables movement; Isometric contractions: for stabilizing and reinforcing the response.~Conventional therapy exercises
Study NCT00849030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex)
Description: 20mg, orally, once daily
Study NCT00849030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastozole (Arimidex) placebo
Description: 1mg, orally, once daily
Study NCT00849030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen (Nolvadex) placebo
Description: 20mg, orally, once daily
Study NCT00848146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopically assisted Laparoscopic Cholecystectomy Surgery
Description: Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
Study NCT02299453 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IPT
Description: Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
Study NCT02184845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant NobelActive 3.0
Study NCT02022254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
Study NCT02022254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Semaglutide placebo will be administered s.c.
Study NCT02022254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
Study NCT02022254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
Study NCT01534663 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine and Fish Oil Supplementation
Description: This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
Study NCT01534663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
Study NCT01607918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)
Description: D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
Study NCT01607918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D1-D14: (lansoprazole + clarithromycin + amoxicillin)
Description: D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
Study NCT02468518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E capsule
Description: Capsules will be distributed to each participant free of cost
Study NCT02468518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E capsule
Description: Capsules will be distributed to each participant free of cost
Study NCT03166345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment of Thin Endometrium
Description: This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
Study NCT05956561 — intervention group
Intervention type: OTHER
Intervention: dental implants were placed for all cases while assessing vitamin D levels
Description: vitamin D assessment with measuring implant stability and clinical finding of early failure
Study NCT01874561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Custirsen
Description: Custirsen will be administered iv using an infusion pump over a 2-hour period.
Study NCT01874561 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
Study NCT01874561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
Study NCT00272779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: 300mg Oral capsules for 96 weeks
Study NCT00272779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: 100mg Oral Capsules for 96 weeks
Study NCT00272779 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovi-Emtricitabine (TDF/FTC) tablet
Description: One tablet with 300 mg - 200 mg once a day for 96 weeks.
Study NCT00715416 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nitinol stent
Description: Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
Study NCT00715416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nitinol stent
Description: Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
Study NCT04557761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: microMend®
Description: microMend® is a novel wound closure device that consists of arrays of tiny staples, known as Microstaples, which are attached to a backing material that is the size and shape of a butterfly closure. The Microstaples enable secure attachment of the device to the skin, allowing for the safe closure of wounds associated with surgery and traumatic injuries, such as lacerations. microMend is listed with the FDA and is available for sale in the United States.
Study NCT04557761 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Closure with Sutures
Description: The Subject's laceration will be closed with sutures per regular institutional policies and procedures.
Study NCT00715416 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nitinol Stent Placement
Description: Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
Study NCT00902395 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Oral midazolam 1.0 mg/kg (maximum 20 mg)
Study NCT00902395 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Protective stabilization
Description: Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
Study NCT00902395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam, ketamine
Description: Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
Study NCT04061928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1
Description: 2 times PD-1 (240mg) combined with preoperative chemoradiotherapy，then another 2 times PD-1 before operation. 4 times PD-1 combined with postoperative chemotherapy.
Study NCT01766193 — intervention group
Intervention type: PROCEDURE
Intervention: vaginal delivery
Study NCT01766193 — intervention group
Intervention type: PROCEDURE
Intervention: forceps extraction
Description: vaginal delivery by forceps extraction
Study NCT01766193 — intervention group
Intervention type: PROCEDURE
Intervention: vacuum extraction
Description: vaginal delivery by vacuum extraction
Study NCT01766193 — intervention group
Intervention type: PROCEDURE
Intervention: cesarean section
Study NCT04807491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular Re-Education
Description: After the baseline assessment, the participant in the control will receive Neuromuscular Re-Education. The duration of session will be 45 minutes.Neuromuscular Re-Education: For initiation (acute phase): Active-assisted exercise,Massage and stretch for affected side.For Facilitation ,Active-assisted exercise.For Movement control:Massage and stretching for facial retraction,Assisted and active exercises on involved side.~For Relaxation,Thermotherapy,Relaxation exercises,Alternating rhythmic movements.~Conventional therapy exercises
Study NCT00181298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
Study NCT00181298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
Study NCT03648450 — intervention group
Intervention type: OTHER
Intervention: Propeller EMD
Description: Propeller electronic monitoring device is a sensor that fits on top of inhalers and uses Bluetooth connection to cell phones to remind patients to take their medication.
Study NCT03638011 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exparel
Description: Bilateral TAP Blocks with combination of regular Bupivacaine and EXPAREL
Study NCT00117962 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: 400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
Study NCT00117962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC = 5 q 21 days for 4 cycles
Study NCT00117962 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
Study NCT00117962 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
Study NCT03458806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AS Algorithm 1
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
Study NCT03458806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: AS Algorithm 2
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater aortic stenosis from controls having any findings other than moderate-to-severe or greater aortic stenosis.
Study NCT03458806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR Algorithm 1
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having structurally normal hearts with no greater than mild valvular heart disease at any location.
Study NCT03458806 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MR Algorithm 2
Description: Machine learning algorithm, generated from ECG and PCG recordings, distinguishing moderate-to-severe or greater mitral regurgitation from controls having any findings other than moderate-to-severe or greater mitral regurgitation.
Study NCT03265392 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bread
Description: Serving of wheat bread providing 50 g of carbohydrates
Study NCT03194425 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pelvic floor EMG
Description: Define pelvic floor EMG template measured by probe
Study NCT03846947 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR Fingerprinting
Description: The MR fingerprinting technique requires less than 15 minutes total and will be added before and after the standard MRI sequence.
Study NCT00755001 — intervention group
Intervention type: DEVICE
Intervention: BiHapro hip stem with PPS Ti+Plasma HA
Description: BiHapro hip stem with PPS Ti+Plasma HA
Study NCT00755001 — intervention group
Intervention type: DEVICE
Intervention: BiHapro hip stem with PPS Ti+BoneMaster HA
Description: BiHapro hip stem with PPS Ti+BoneMaster HA
Study NCT01498991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AMES Treatment
Description: The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
Study NCT02123329 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist delivered smoking cessation program
Description: The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.~To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.~• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems
Study NCT02123329 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control arm (i.e: regular care)
Description: Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
Study NCT01086683 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial rehabilitation course
Description: Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
Study NCT01584024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resin infiltration
Description: Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.~ICON product: FDA-510(k): K100062
Study NCT01584024 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham treatment
Description: Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
Study NCT02649933 — intervention group
Intervention type: DEVICE
Intervention: Watch PAT 200
Description: screening of OSA with Watch PAT 200
Study NCT00753636 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dynacirc CR (Isradipine)
Description: Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
Study NCT01568944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Antibiotic and Oral Rinse
Description: PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
Study NCT01568944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
Study NCT05230927 — intervention group
Intervention type: OTHER
Intervention: Multidisciplinary Rehabilitation
Description: All patients admitted to an inpatient rehabilitation program will undergo medical history collection, physical, clinical, and functional examination, exercise testing, educational sessions, exercise training (cycle ergometer/treadmill, arm ergometer, breathing, and strength exercises where indicated, calisthenics exercises), psychological counseling, and metabolic evaluation with a personalized diet when needed.
Study NCT01568944 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standard Treatment
Description: Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers